EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Psilocybin and Ibogaine in Cocaine‐Seeking: Extinction Enhancement Without Relapse Prevention

Isis Rita Anzel Koutrouli, Vojtěch Brejtr, Marek Schwendt, Kacper Witek iD, Chrysostomos Charalambous, Kristýna Aleksič, Nina Miniariková, Eva Lhotková, Martin Toman, Marek Nikolič, Radek Jurok, Petra Cihlářová und 5 weitere

Addiction Biology · 2026-03 · 31 (3)

DOI: 10.1111/adb.70111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Addiction Biology, online erschienen am 04.03.2026. Verfasst von Isis Rita Anzel Koutrouli und 16 weiteren Autor:innen. Beteiligte Einrichtung: Psychedelic Research Centre, National Institute of Mental Health, Klecany, Czech Republic. Hauptthemen laut MEDLINE: Extinction, Psychological, Ibogaine, Hallucinogens, Psilocybin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Charles University research program Cooperatio-Neurosciences, Long-term Conceptual Development of Research Organisation, Ministry of the Interior of the Czech Republic/Ministerstvo Vnitra České Republiky, PSYRES (Psychedelic Research Foundation) (https://psyresfoundation.eu).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psychedelics have emerged as potential therapeutics for substance use disorders, yet preclinical data validating their efficacy remain limited. Here, we investigated the effects of a clinically inspired dose‐escalation protocol of psilocybin and ibogaine on extinction and cue‐induced reinstatement in Wistar male rats following intravenous cocaine self‐administration (IVSA). Rats were trained on a fixed ratio 1 (FR1) schedule with cocaine dose‐escalation during the acquisition phase (0.25 mg/kg/infusion, followed by 0.5 mg/kg/infusion). Following acquisition, animals were randomised into treatment groups and then subjected to 10 days of extinction. Psilocybin (1.25 mg/kg and 5 mg/kg) or ibogaine (10 mg/kg and 40 mg/kg) was administered subcutaneously and intraperitoneally, respectively, on extinction days 1 and 5. A cue‐induced reinstatement test was conducted 6 days after the last treatment. Both treatments significantly modulated behaviour during extinction; psilocybin reduced active lever pressing 1 day after the second dose, with a nonsignificant reduction already apparent after the first dose, while the effect of ibogaine was significant even after the first administration. However, neither compound significantly altered reinstatement behaviour, although psilocybin showed a trend toward attenuation. The applied treatment had no side effects on general locomotor activity or anxiety‐like behaviour, as measured in the open field test 24 h after each administration. These findings support a role for psilocybin and ibogaine in facilitating extinction learning and suggest possible protective effects against relapse, warranting further research into their antiaddictive efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extinction, PsychologicalIbogaineHallucinogensPsilocybinCocaineDrug-Seeking BehaviorCocaine-Related DisordersAnimalsMaleRats, WistarRatsSelf AdministrationDopamine Uptake InhibitorsSecondary PreventionCuesDose-Response Relationship, DrugConditioning, OperantBehavior, Animal

Stichwörter der Autor:innen

Wistar rataddictioncocaineibogainepsilocybinpsychedelicsreinstatementself‐administration

Substanzen

IbogaineHallucinogensPsilocybinCocaineDopamine Uptake Inhibitors

Autor:innen und Institutionen

  • Psychedelic Research Centre, National Institute of Mental Health, Klecany, Czech Republic.
  • 3rd Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Czech Institute of Informatics, Robotics and Cybernetics, Prague, Czech Republic.
  • Department of Psychology, University of Florida, Gainesville, Florida, USA.
  • Department of Drug Addiction Pharmacology, Maj Institute of Pharmacology Polish Academy of Sciences, Kraków, Poland.
  • Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Prague, Czech Republic.

ORCID-Profile: Kacper Witek, Martin Kuchař

Förderung

  • Charles University research program Cooperatio-Neurosciences, Long-term Conceptual Development of Research Organisation
  • Ministry of the Interior of the Czech Republic/Ministerstvo Vnitra České Republiky
  • PSYRES (Psychedelic Research Foundation) (https://psyresfoundation.eu)
  • Ministerstvo Vnitra České Republiky

Zitieren

APA

Koutrouli, I. R. A., Brejtr, V., Schwendt, M., Witek, K., Charalambous, C., Aleksič, K., Miniariková, N., Lhotková, E., Toman, M., Nikolič, M., Jurok, R., Cihlářová, P., Mazoch, V., Ryšánek, P., Kuchař, M., Šíchová, K., & Páleníček, T. (2026). Psilocybin and Ibogaine in Cocaine‐Seeking: Extinction Enhancement Without Relapse Prevention. Addiction Biology, 31(3). https://doi.org/10.1111/adb.70111

Vancouver

Koutrouli IRA, Brejtr V, Schwendt M, Witek K, Charalambous C, Aleksič K, et al. Psilocybin and Ibogaine in Cocaine‐Seeking: Extinction Enhancement Without Relapse Prevention. Addiction Biology. 2026;31(3). doi:10.1111/adb.70111

BibTeX
@article{Koutrouli2026,
  author = {Koutrouli, Isis Rita Anzel and Brejtr, Vojtěch and Schwendt, Marek and Witek, Kacper and Charalambous, Chrysostomos and Aleksič, Kristýna and Miniariková, Nina and Lhotková, Eva and Toman, Martin and Nikolič, Marek and Jurok, Radek and Cihlářová, Petra and Mazoch, Vladimír and Ryšánek, Pavel and Kuchař, Martin and Šíchová, Klára and Páleníček, Tomáš},
  title = {Psilocybin and Ibogaine in Cocaine‐Seeking: Extinction Enhancement Without Relapse Prevention},
  journal = {Addiction Biology},
  year = {2026},
  volume = {31},
  number = {3},
  doi = {10.1111/adb.70111}
}
Kostenlos starten →